BioCentury
ARTICLE | Clinical News

Tesaro unblinds data to patient in niraparib trial

July 9, 2015 12:42 AM UTC

Tesaro Inc. (NASDAQ:TSRO) unblinded a treatment assignment to a single patient in the Phase III NOVA trial of niraparib ( MK-4827) to treat ovarian cancer, upon the patient's request. CEO Lonnie Moulder told BioCentury the information was unblinded according to pre-existing mechanisms in the study's protocol.

A petition to release the information said the patient had requested unblinding of her treatment -- niraparib or placebo -- to determine her eligibility to receive another therapy. ...